Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Dynavax Technologies Corp is demonstrating promising progress in its vaccine candidates, with reported vaccine response rates for the selected 100ug dose being comparable to those of Shingrix, alongside notably improved tolerability. The company has received encouraging results regarding tolerability and CD4+ T-cell responses for its Z-1018 shingles vaccine candidate, aligning with management's immunogenicity and tolerability goals. This positive momentum, along with the substantial revenue generation from its existing products CpG 1018 and HEPLISAV-B, underscores a favorable outlook for Dynavax's financial performance.

Bears say

Dynavax Technologies Corp faces significant challenges in advancing its clinical candidates, as future products may fail to meet efficacy and safety standards necessary for approval and commercialization. The company also contends with potential difficulties in effective commercialization due to market conditions, strong competition, and internal factors that could hinder growth. Additionally, Dynavax may struggle to secure acceptable partnership terms for its candidates, further jeopardizing the success of its commercial launches.

Dynavax Technologies (DVAX) has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Hold based on their latest research and market trends.

According to 4 analysts, Dynavax Technologies (DVAX) has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.